ALCOX Stock Overview
Nicox S.A. operates as an ophthalmology company in France and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Nicox S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.38 |
| 52 Week High | €0.65 |
| 52 Week Low | €0.30 |
| Beta | 0.89 |
| 1 Month Change | -3.85% |
| 3 Month Change | -10.71% |
| 1 Year Change | -35.23% |
| 3 Year Change | -91.00% |
| 5 Year Change | -93.04% |
| Change since IPO | -99.63% |
Recent News & Updates
Shareholder Returns
| ALCOX | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0.1% | -0.06% | -0.2% |
| 1Y | -35.2% | -4.3% | 2.4% |
Return vs Industry: ALCOX underperformed the French Biotechs industry which returned -8.2% over the past year.
Return vs Market: ALCOX underperformed the French Market which returned 4% over the past year.
Price Volatility
| ALCOX volatility | |
|---|---|
| ALCOX Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALCOX has not had significant price volatility in the past 3 months.
Volatility Over Time: ALCOX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 28 | Gavin Spencer | www.nicox.com |
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial.
Nicox S.A. Fundamentals Summary
| ALCOX fundamental statistics | |
|---|---|
| Market cap | €18.75m |
| Earnings (TTM) | -€17.36m |
| Revenue (TTM) | €3.57m |
5.2x
P/S Ratio-1.1x
P/E RatioIs ALCOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCOX income statement (TTM) | |
|---|---|
| Revenue | €3.57m |
| Cost of Revenue | €16.90m |
| Gross Profit | -€13.33m |
| Other Expenses | €4.03m |
| Earnings | -€17.36m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | -372.97% |
| Net Profit Margin | -485.70% |
| Debt/Equity Ratio | 44.8% |
How did ALCOX perform over the long term?
See historical performance and comparison